Sunshine Biopharma Stock Price, News & Analysis
SBFMW
NASDAQ
Company Description
Sunshine Biopharma Inc. (SBFMW) is a pharmaceutical company based in Montreal, Quebec, Canada. They specialize in developing life-saving medicines in areas such as oncology and antivirals. The company's proprietary drug development program includes K1.1 mRNA for liver cancer, SBFM-PL4, a PLpro protease inhibitor for SARS Coronavirus infections, and Adva-27a for pancreatic cancer. With reportable segments in Generic Pharmaceuticals and OTC Products, Sunshine Biopharma primarily generates revenue from the Generic Pharmaceuticals segment.
Stock Performance
$0.1469
0.00%
0.00
Last updated: September 28, 2025 at 14:12
40.14 %
Performance 1 year
$0.0
3.1M
Latest News
SEC Filings
Financial Highlights
$9,410,230
Revenue (TTM)
$1,770,834
Net Income (TTM)
$0.82
$2,987,267
Operating Cash Flow
0.19%
0.22%
Upcoming Events
Short Interest History
Last 12 Months
Loading short interest data...
Days to Cover History
Last 12 Months
Loading days to cover data...
Frequently Asked Questions
What is the current stock price of Sunshine Biopharma (SBFMW)?
The current stock price of Sunshine Biopharma (SBFMW) is $0.1469 as of September 26, 2025.
What is the revenue (TTM) of Sunshine Biopharma (SBFMW) stock?
The trailing twelve months (TTM) revenue of Sunshine Biopharma (SBFMW) is $9,410,230.
What is the net income of Sunshine Biopharma (SBFMW)?
The trailing twelve months (TTM) net income of Sunshine Biopharma (SBFMW) is $1,770,834.
What is the earnings per share (EPS) of Sunshine Biopharma (SBFMW)?
The diluted earnings per share (EPS) of Sunshine Biopharma (SBFMW) is $0.82 on a trailing twelve months (TTM) basis. Learn more about EPS .
What is the operating cash flow of Sunshine Biopharma (SBFMW)?
The operating cash flow of Sunshine Biopharma (SBFMW) is $2,987,267. Learn about cash flow.
What is the profit margin of Sunshine Biopharma (SBFMW)?
The net profit margin of Sunshine Biopharma (SBFMW) is 0.19%. Learn about profit margins.
What is the operating margin of Sunshine Biopharma (SBFMW)?
The operating profit margin of Sunshine Biopharma (SBFMW) is 0.22%. Learn about operating margins.
What is the gross margin of Sunshine Biopharma (SBFMW)?
The gross profit margin of Sunshine Biopharma (SBFMW) is 0.36%. Learn about gross margins.
What is the current ratio of Sunshine Biopharma (SBFMW)?
The current ratio of Sunshine Biopharma (SBFMW) is 5.00, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.
What is the gross profit of Sunshine Biopharma (SBFMW)?
The gross profit of Sunshine Biopharma (SBFMW) is $3,422,866 on a trailing twelve months (TTM) basis.
What is the operating income of Sunshine Biopharma (SBFMW)?
The operating income of Sunshine Biopharma (SBFMW) is $2,054,655. Learn about operating income.
What is Sunshine Biopharma Inc. known for?
Sunshine Biopharma is known for developing life-saving medicines in therapeutic areas like oncology and antivirals.
What are some of the core projects of Sunshine Biopharma Inc.?
Sunshine Biopharma is working on projects like K1.1 mRNA for liver cancer, SBFM-PL4 for SARS Coronavirus infections, and Adva-27a for pancreatic cancer.
How does Sunshine Biopharma Inc. generate revenue?
Sunshine Biopharma primarily generates revenue from its Generic Pharmaceuticals segment.
Where is Sunshine Biopharma Inc. located?
Sunshine Biopharma Inc. is based in Montreal, Quebec, Canada.
Who can be contacted for more information about Sunshine Biopharma Inc.?
You can contact CFO Camille Sebaaly at 514-814-0464 or camille.sebaaly@sunshinebiopharma.com for more information.
What are the two reportable segments of Sunshine Biopharma Inc.?
Sunshine Biopharma Inc.'s reportable segments are Generic Pharmaceuticals and OTC Products.
What is the focus of Sunshine Biopharma Inc.'s drug development program?
Sunshine Biopharma's drug development program focuses on developing life-saving medicines in therapeutic areas like oncology and antivirals.
What is the significance of K1.1 mRNA in Sunshine Biopharma Inc.'s projects?
K1.1 mRNA is targeted for liver cancer and is a key project in Sunshine Biopharma's drug development program.
How is SBFM-PL4 relevant to Sunshine Biopharma Inc.'s work?
SBFM-PL4 is a PLpro protease inhibitor developed by Sunshine Biopharma for SARS Coronavirus infections.
What is Adva-27a and its role in Sunshine Biopharma Inc.'s projects?
Adva-27a is a drug developed by Sunshine Biopharma for pancreatic cancer and is a significant part of their drug development program.